{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-275384","form_type":"8-K","ticker":"BNTC","cik":"0001808898","company_name":"Benitec Biopharma Inc.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.570358+00:00","generated_at":"2026-06-08T05:21:13.989500+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Benitec Biopharma Q1 net loss $6M; 19 OPMD subjects enrolled; BB-301 dosing expected Dec/Jan","bullets":["Net loss of $6.0M ($2.76 per share) vs $5.1M ($7.98 per share) in Q1 FY2023; higher share count reduced per-share loss.","Cash and equivalents $25.9M at Sep 30, 2023, up from $2.5M at Jun 30, 2023, extending runway.","R&D expense $4.4M (up 66% YoY) driven by BB-301 clinical development; G&A $1.6M (down 19% YoY).","19 subjects enrolled in OPMD Natural History Study as of Oct 2023; first BB-301 dose planned Dec 2023 or Jan 2024.","FDA IND clearance received; Canadian REB submission completed; interim safety/efficacy data expected within 12 months of first dose."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-275384","json":"https://secwatch.observer/filing/0001193125-23-275384.json","markdown":"https://secwatch.observer/filing/0001193125-23-275384.md","text":"https://secwatch.observer/filing/0001193125-23-275384.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1808898/000119312523275384/0001193125-23-275384-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1808898/000119312523275384/d85932d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T05:21:13.989500+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c0a1a904117de6c0d976998d0b2118a67dbf2e56","claim":"Benitec Biopharma Inc. reported First Fiscal Quarter ended September 30, 2023 results: revenue $0.","evidence_excerpt":"OPMD patient screening and enrollment to begin in Canada. Financial Highlights First Quarter 2024 Financial Results Total Revenues for the quarter ended September 30, 2023, were $0 compared to $0 for the quarter ended September 30, 2022. Total Expenses for the quarter ended September 30, 2023 were $5.9 million compared to $4.6 million for the quarter ended","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1808898/000119312523275384/0001193125-23-275384-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"First Fiscal Quarter ended September 30, 2023"},{"label":"Revenue","value":"$0"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}